ClinicalTrials.gg
CompletedNCT03153774PRESAR-HFUpdated Nov 9, 2026

Assessments of Sarcopenia Prevalence in Chronic Heart Failure Patients and in Subjects Before TAVI

An interventional study of Assessment of sarcopenia prevalence in Sarcopenia and Chronic Heart Failure, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Nov 2014, registered May 2017).
Updated Nov 9, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
249
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Sarcopenia by University Hospital, Clermont-Ferrand — 4 open to participants now, 4 under way, none of them phase 3. Sarcopenia · University Hospital, Clermont-Ferrand.

Enrollment
4th of 10
249 · median 130
Started
2014
the only one that year
No phase
10 of 12
4 open now
Registered
3rd of 12
by date

Among the 12 studies in Sarcopenia by University Hospital, Clermont-Ferrand, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2014, is one of 10 with no phase, and was the 3rd registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

4 of the 12 studies in Sarcopenia by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Sarcopenia by University Hospital, Clermont-Ferrand, or all of them as a file.
02

Study summary

The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.

The loss of muscle mass in chronic heart failure patients is a prognostic factor for sarcopenia. The purpose was to identify in these patients signs of sarcopenia for a better management.

Read the detailed description

Age-related muscle loss, termed sarcopenia, affects 10% of elderly subjects aged 60-70 years and more than 30% above the age of 80. The concept of sarcopenia has been supported by the recent findings of muscular atrophy which was related to the decrease of protein synthesis because of the "anabolic resistance", affecting the muscular fibers type II. In fact, sarcopenia could be a consequence of chronic disease and not only an issue in the elderly people. The diagnosis is assessed by the weak muscle mass and the muscle strength and function. A description of these muscle parameters has been described in a study of 200 patients with NYHA class II-III and showed that 19,5 % have a decrease in muscle mass. They also showed that these patients have a lower functional ability. These findings prompted us to investigate the prevalence of sarcopenia in chronic heart failure subjects for a better management of these patients.

03

Conditions studied

  • Sarcopenia
  • Chronic Heart Failure

Keywords

  • Sarcopenia
  • Heart failure (HF)
  • The trans aortic valvular implantation (TAVI)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Major patients (>18 years)
  • Men or women
  • Hospitalized in pre- trans aortic valvular implantation assessment in the cardiology department of the university hospital centre of Clermont-Ferrand or
  • Patients with chronic heart failure in charge in the hospital of Clermont-Ferrand or convalescence in the pneumocardiological clinic of Durtol

Exclusion criteria

Exclusion Criteria:

  • Patient not affiliated to social security
  • Inability to understand the information consent letter
  • Not having signed
  • Has a mental or legal incapacitation and is unable to provide informed consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
249 participants (actual)

Study arms

  • Experimental
    Heart failure patients

    The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.

    Diagnostic Test: Assessment of sarcopenia prevalence

  • Experimental
    TAVI patients

    The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.

    Diagnostic Test: Assessment of sarcopenia prevalence

Interventions

  • Diagnostic testAssessment of sarcopenia prevalence

    Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test

06

What researchers measure

Primary outcomes

  1. Bioimpedance analysis data

    Fat-free mass and body fat mass will be combined to report BMI in Kg/m2

    Time frame: at day 1

  2. Short physical performance battery

    Balance test, 4-min walking test, 5 times getting-up test

    Time frame: at day 1

  3. Handgrip test

    Time frame: at day 1

Secondary outcomes

  1. Blood draw for serum creatinine in umol/L

    Measure of inflammation

    Time frame: at day 1

  2. CRP in mg/L

    Measure of inflammation

    Time frame: at day 1

  3. platelets in Giga/L

    Measure of inflammation

    Time frame: at day 1

  4. complete blood count CBC (white blood cells in Giga/L and red blood cells in Tera/L)

    Measure of inflammation

    Time frame: at day 1

  5. urea in mmol/L

    Measure of inflammation

    Time frame: at day 1

  6. albumin in g/L

    Measure of inflammation

    Time frame: at day 1

  7. NT-ProBNP in ng/L

    Measure of inflammation

    Time frame: at day 1

  8. Electrocardiogram

    Parameter which may interfere with sarcopenia

    Time frame: at day 1

  9. Trans-thoracic echography

    Parameter which may interfere with sarcopenia

    Time frame: at day 1

07

Study locations

1 site
  • CHU Clermont-Ferrand
    Clermont-Ferrand, Auvergne 63003, France
08

References and documents

Publications

  • Eschalier R, Massoullie G, Boirie Y, Blanquet M, Mulliez A, Tartiere PL, Anker S, D'Agrosa Boiteux MC, Richard R, Jean F, Combaret N, Souteyrand G, Riocreux C, Pereira B, Motreff P, Stolt P, Rossignol P, Clerfond G. Sarcopenia in patients after an episode of acute decompensated heart failure: An underdiagnosed problem with serious impact. Clin Nutr. 2021 Jun;40(6):4490-4499. doi: 10.1016/j.clnu.2020.12.033. Epub 2021 Jan 9. PubMed 33483182 ↗
  • Blanquet M, Massoulie G, Boirie Y, Guiguet-Auclair C, Mulliez A, Anker S, Boiteux MD, Jean F, Combaret N, Souteyrand G, Riocreux C, Pereira B, Motreff P, Rossignol P, Clerfond G, Eschalier R. Handgrip strength to screen early-onset sarcopenia in heart failure. Clin Nutr ESPEN. 2022 Aug;50:183-190. doi: 10.1016/j.clnesp.2022.05.019. Epub 2022 Jun 6. PubMed 35871922 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Nov 2018, 48 months.

Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 48 months is above that.

Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2017
First posted
May 15, 2017
StartActual
Nov 3, 2014
Primary completionActual
Nov 30, 2018
CompletionActual
Dec 31, 2018
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 9, 2026
Enrollment
300 (estimated)→249 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Status unknown→Completed
    Enrollment 300 (estimated)→249 (actual)
    + 5 other changes: verification date, date precision, contact details, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03153774
Responsible party
Sponsor
First posted
May 15, 2017
Start date
Nov 3, 2014
Primary completion
Nov 30, 2018
Completion
Dec 31, 2018
Last update
Nov 9, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion